Physician profile
Benjamin E Wheeler
NPI 1407171614
$3,192.43
in general payments reported to CMS, 2019-2025
23 companies · $621 in 2025
The $621 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.92 · 2020: $1,040 · 2021: $19.95 · 2022: $104 · 2023: $543 · 2024: $853 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,040.00 | 2020 | |
| Abbvie INC. | $817.00 | 2019-2025 | Linzess, Rinvoq, Creon |
| Janssen Biotech, INC. | $207.74 | 2023-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $200.82 | 2023-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $192.34 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.14 | 2022-2025 | Entyvio, Eohilia |
| Pfizer INC. | $87.34 | 2023-2025 | |
| Ardelyx, INC. | $87.19 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $71.09 | 2024-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $46.67 | 2023 | |
| Amgen INC. | $45.66 | 2023 | Avsola, Amjevita |
| Celltrion USA INC. | $40.82 | 2025 | Vegzelma |
| Phathom Pharmaceuticals, INC. | $38.74 | 2024 | Voquezna |
| Celgene Corporation | $34.36 | 2023-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.97 | 2023 | Xifaxan |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $29.86 | 2025 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $21.58 | 2024 | Iqirvo |
| Ferring Pharmaceuticals INC. | $21.35 | 2025 | Rebyota |
| Vivus LLC | $21.09 | 2024 | Pancreaze |
| Gilead Sciences, INC. | $17.36 | 2024 | |
| Fresenius Kabi USA, LLC | $16.50 | 2023 | |
| Madrigal Pharmaceuticals | $15.41 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $15.40 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.